Effect of PGF2 alpha administration on the release of endogenous PGF2 alpha and oxytocin in indomethacin-treated goats.
Repeated intramuscular injection of 1 mg prostaglandin F2 alpha (PGF2 alpha) during the luteal phase of the oestrous cycle of the goat hastened luteolysis and resulted in rapid increases in jugular concentrations of 13,14-dihydro-15-keto PGF2 alpha (PGFM), the primary metabolite of PGF2 alpha, and of oxytocin; similar injections of PGF2 alpha in indomethacin-treated goats had a reduced effect on PGFM and oxytocin concentrations, and failed to induce luteolysis. The same injections of PGF2 alpha were without effect on PGFM and oxytocin concentrations in ovariectomised goats. The results suggest that exogenous PGF2 alpha, or endogenous PGF2 alpha released at luteolysis, may induce the release of ovarian oxytocin in the goat.
D000818:Animals; D015237:Dinoprost; D004971:Estrus / Q000187:drug effects*; D005260:Female; D006041:Goats / Q000502:physiology*; D007213:Indomethacin / Q000494:pharmacology*; D008183:Luteal Phase / Q000187:drug effects; D003341:Luteolysis / Q000187:drug effects; D010053:Ovary / Q000502:physiology; D010121:Oxytocin / Q000097:blood*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood*; D011460:Prostaglandins F / Q000097:blood* / Q000494:pharmacology*; D011863:Radioimmunoassay / Q000662:veterinary
D011460:Prostaglandins F; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost; D007213:Indomethacin